US › Healthcare

Sonoma Pharmaceuticals Inc (SNOA)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$1.26+2.44%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$6.4M

Revenue YoY

+59.6%

Net profit

$-330,000

EPS

$0.02

Net margin

-5.2%

Key statistics

Market cap

$6.3M

Forward P/E

46.1

P/B

0.94

Book value

$1.72

EPS (TTM)

$-1.22

52-week high

$4.60

52-week low

$0.85

50-day MA

$1.26

200-day MA

$2.13

Beta

1.31

Analyst view

Analysts rate Sonoma Pharmaceuticals Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $12.00.

Shareholding

Insiders

0.42%

Institutions

2.31%

Largest institutional holders

Fund	Stake
Geode Capital Management, LLC	0.42%
Vanguard Capital Management, LLC	0.39%
DRW Securities, LLC	0.25%
Mckinley Carter Wealth Services Inc	0.23%
Morgan Stanley - Brokerage Accounts	0.04%
Citigroup Inc	0.03%
Tower Research Capital LLC	0.03%
Advisor Group Holdings, Inc.	0.01%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sonoma Pharmaceuticals Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.